{"disease":{"id":"nonq-wave-myocardial-infarction","name":"NonQ wave myocardial infarction","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":2,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"eptifibatide","indication_name":"NonQ wave myocardial infarction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Integrilin","generic_name":"EPTIFIBATIDE","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Integrin alpha-IIb/beta-3","drug_class":"Platelet Aggregation Inhibitor [EPC]","quality_score":75,"revenue":null,"mechanism":"Integrilin blocks the binding of fibrinogen to platelets, preventing them from clumping together and forming clots."},{"drug_id":"integrilin","indication_name":"NonQ wave myocardial infarction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"integrilin","company_name":"University of Cincinnati","drug_phase":"phase_1","molecular_target":"Integrin alpha-IIb/beta-3","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}